Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 2/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.39 |
| ▸ | HTR6 | P50406 | 5/20 | 0.36 |
| ▸ | HTR2A | P28223 | 3/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3703494 | 0.92 | NFE2L2 (0.33) | COMTNFE2L2HTR6HTR2AKCNH2 | |
| SCHEMBL476464 | 0.88 | NFE2L2 (0.41) | NFE2L2HSD11B1PTGS2 | |
| SCHEMBL476451 | 0.84 | HTR6 (0.39) | COMTNFE2L2HTR6HTR2APTGS2 | |
| SCHEMBL476427 | 0.84 | HTR6 (0.36) | NFE2L2HTR6 | |
| SCHEMBL4123859 | 0.83 | CA1 (0.35) | HTR6PTGS2 | |
| SCHEMBL3697370 | 0.82 | NFE2L2 (0.47) | NFE2L2 | |
| SCHEMBL476288 | 0.81 | COMT (0.41) | COMTNFE2L2HTR6PTGS2 | |
| SCHEMBL3702681 | 0.79 | NFE2L2 (0.38) | NFE2L2HTR6 | |
| SCHEMBL476271 | 0.78 | HTR6 (0.40) | COMTHTR6HTR2AKCNH2 | |
| Hydrochloric Acid SCHEMBL476306 | 0.77 | HTR6 (0.40) | COMTHTR6HTR2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2412713-B1 | PYRAZOLE COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-8895588-B2 | Pyrazole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895588-B2 | Pyrazole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895588-B2 | Pyrazole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20120095057-A1 | PYRAZOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120095057-A1 | PYRAZOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120095057-A1 | PYRAZOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-2412713-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2012-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095057-A1 | PYRAZOLE COMPOUND | CEL, HRH2, GIPR | COMT 4484/4885NFE2L2 3984/4885HTR6 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.